Gene Ontology annotation through association of InterPro records with GO terms
Manual transfer of experimentally-verified manual GO annotation data to orthologs by curator judgment of sequence similarity
Gene Ontology annotation based on curation of immunofluorescence data
Electronic Gene Ontology annotations created by ARBA machine learning models
Combined Automated Annotation using Multiple IEA Methods
Role of EDEM in the release of misfolded glycoproteins from the calnexin cycle.
Derlin-2 and Derlin-3 are regulated by the mammalian unfolded protein response and are required for ER-associated degradation.
EDEM1 recognition and delivery of misfolded proteins to the SEL1L-containing ERAD complex.
A dual role for EDEM1 in the processing of rod opsin.
Mannose trimming is required for delivery of a glycoprotein from EDEM1 to XTP3-B and to late endoplasmic reticulum-associated degradation steps.
A shared endoplasmic reticulum-associated degradation pathway involving the EDEM1 protein for glycosylated and nonglycosylated proteins.
The role of EDEM2 compared with EDEM1 in ricin transport from the endoplasmic reticulum to the cytosol.
EDEM2 initiates mammalian glycoprotein ERAD by catalyzing the first mannose trimming step.
-
All endogenous EDEMs possess mannosidase activity; EDEM3 and to a lesser extent EDEM1 perform the second trimming step (Man8B to Man7), resolving the mannosidase-versus-lectin controversy.
-
EDEM1 has the weakest mannosidase activity of the three EDEMs and can also enhance gpERAD independently of catalysis (lectin-like) when overexpressed.
Mannosidase activity of EDEM1 and EDEM2 depends on an unfolded state of their glycoprotein substrates.
-
In vitro, EDEM1 (and EDEM2) mannosidase activity is modest on free oligosaccharides and native glycoproteins but significantly higher on a denatured glycoprotein, explaining how slow background trimming becomes selective for misfolded substrates; the EDEMs associate with oxidoreductases including PDI and TXNDC11.
EDEM1 Drives Misfolded Protein Degradation via ERAD and Exploits ER-Phagy as Back-Up Mechanism When ERAD Is Impaired.
Turnover of EDEM1, an ERAD-enhancing factor, is mediated by multiple degradation routes.
-
EDEM1 is itself turned over by both ERAD (SEL1L/Hrd1, YOD1, XTP3B, ERdj3, VIMP, BAG6, JB12) and autophagy in folded-state-dependent manner; OS9 binds EDEM1 but did not drive its turnover. EDEM1 has a fast half-life (~3 h) and exists in soluble and membrane-associated forms.
ER-to-lysosome-associated degradation acts as failsafe mechanism upon ERAD dysfunction.
-
Pharmacologic or genetic inhibition of ERAD components, including silencing EDEM1, reroutes canonical ERAD clients (NHK, BACE457delta) to degradative endolysosomes via the ER-phagy receptor FAM134B and the LC3 lipidation machinery.
Mechanisms of substrate processing during ER-associated protein degradation.
EDEM1,3 hydrolyse (GlcNAc)2 (Man)8b to (GlcNAc)2 (Man)5
UniProt entry Q92611 (EDEM1_HUMAN), ER degradation-enhancing alpha-mannosidase-like protein 1
-
Single-pass type II ER membrane GH47 protein that extracts misfolded glycoproteins from the calnexin cycle and targets them for ERAD (N-glycan-independent, via SEL1L); has low mannosidase activity (Man8GlcNAc2 to Man7GlcNAc2); interacts with SEL1L, DERL2, DERL3.